Articles by Katie Kosko
Michael Styler, MD, received the NCCN 2025 Outstanding Contributor Award for his commitment to improving cancer care.
Targeted therapies reshape CLL care as experts weigh time-limited vs indefinite frontline treatment strategies.
Novel agents are reshaping treatment for double-refractory CLL, offering new hope for this tough-to-treat disease.
Mayo Clinic researchers released the data on relapsed or refractory patients with AML who were a median age of 65 years.
The trial's treatment regimen included single-agent dasatinib for the first three months, followed by venetoclax.
Investigators reviewed cladribine in combination with low dose cytarabine (LDAC) and venetoclax.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.